ACADIA Pharmaceuticals Inc. (ACAD) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は San Diego, CA, アメリカ. 現CEOは Catherine E. Owen Adams.
ACAD を有する IPO日 2004-05-27, 653 名の正社員, に上場 NASDAQ Global Select, 時価総額 $3.75B.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, specializing in the development and commercialization of small molecule drugs for central nervous system disorders. The company's flagship product, NUPLAZID (pimavanserin), is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes multiple late-stage candidates such as pimavanserin for Alzheimer's disease psychosis and schizophrenia, Trofinetide for Rett syndrome, ACP-044 for acute and chronic pain management, and ACP-319 for cognitive impairment in schizophrenia and Alzheimer's disease. Founded in 1993, ACADIA remains focused on addressing significant unmet medical needs in neuropsychiatric and neurological conditions.
